Skip to content
MarketScale
‹ Back to IndustriesSciences

Scientists Create Efficient Artificial Photosynthesis, and the Promise of Clean Energy

Photosynthesis is one of the most efficient ways known to harvest solar energy to convert into chemical energy. As such, it’s a demonstration of how nature has succeeded through the process of natural selection where we have failed through rational construction and experimentation in trying to create artificial photosynthesis. That is, until now.  The Proceedings…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences ·
Share

Key takeaways

01

Photosynthesis is one of the most efficient ways known to harvest solar energy to convert into chemical energy.

02

As such, it’s a demonstration of how nature has succeeded through the process of natural selection where we have failed through rational construction and experimentation in trying to create artificial photosynthesis.

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Start free

Photosynthesis is one of the most efficient ways known to harvest solar energy to convert into chemical energy. As such, it’s a demonstration of how nature has succeeded through the process of natural selection where we have failed through rational construction and experimentation in trying to create artificial photosynthesis. That is, until now. 

The Proceedings of the National Academy of Science recently published a paper explaining how a team of scientists from the U.S. and China have created a simple catalyst capable of using sunlight to oxidize water into oxygen and hydrogen gases. This catalyst is simply two iridium atoms connected by a single oxygen atom (Ir2O), all of which are on an α-Fe2O3 substrate (α-Fe2O3 is found in nature as hematite, also known as the main form of iron ore). The result is a form of photosynthesis that is similar to natural photosynthesis, but at lower cost and higher efficiencies. 

The Ir2O catalyst is simple, durable, and highly active, and it not only harvests solar energy, but it also stores that energy in chemical bonds. If these catalysts can be scaled up to truly commercial levels of hydrogen gas production, they could radically transform energy production across the globe. After all, the product of these stable iridium dinuclear catalysts—hydrogen gas—is an important alternative fuel precisely because it produces substantial energy when burned with oxygen to create water. A hydrogen-fueled economy would be one that can provide everyone with the fuel and energy we need, without creating any pollution byproducts. These new catalysts thus offer significant hope and promise. 

Unfortunately, iridium is one of the rarest metals on earth, with annual global production at only around 3 tons. While sparse in the earth’s crust, iridium is much more common in meteorites—although mining meteorites won’t happen in the immediate future. This rare metal has found a recent increase in use in a variety of electronics, spark plugs, and devices that need to withstand very high temperatures. Because this iridium dinuclear catalyst is so efficient, however, the scarcity of iridium will hopefully not pose a problem to the further development of these photosynthetic cells.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Sciences Insights

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market.

  • 01$750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production
  • 02400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027
  • 03Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023

Sep 14, 2026

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS Materials and Yokogawa ran an autonomous AI controller on a butadiene distillation column for 35 days and cut steam use 40%. It’s a real operations proof point. It also puts integration and governance gaps front and center.

  • 01A 35-day closed-loop run is a stronger autonomy proof point than a demo, it forces plants to prove handover, fallback, and KPIs over real feed and operating swings.
  • 02Steam reduction claims are compelling, but procurement and ops teams should pin vendors to baselines, operating envelopes, and how off-spec avoidance is measured.
  • 03Agentic AI is showing up as “work management” and “shift checklist” agents before it replaces control engineers, which shifts requirements toward clean, permissioned data access.

Sep 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512